Avacta Group's (AVCT) Buy Rating Reaffirmed at Peel Hunt

Key Points

• Avacta Group's stock received a "buy" rating reaffirmed by Peel Hunt, with a price target of GBX 99, suggesting an 86.44% potential upside from its previous close.
• The company's shares currently trade at GBX 53.10, fluctuating between a 52-week low of GBX 26 and a high of GBX 72.
• Avacta Group specializes in clinical-stage biopharmaceuticals, utilizing its proprietary pre|CISION® platform to enhance drug delivery for cancer therapeutics.

Avacta Group (LON:AVCT - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at Peel Hunt in a research note issued on Tuesday,Digital Look reports. They presently have a GBX 99 price target on the biotechnology company's stock. Peel Hunt's target price would suggest a potential upside of 86.44% from the stock's previous close.

Avacta Group Price Performance

Shares of AVCT stock opened at GBX 53.10 on Tuesday. Avacta Group has a 52-week low of GBX 26 and a 52-week high of GBX 72. The company has a debt-to-equity ratio of 52.53, a quick ratio of 4.96 and a current ratio of 1.29. The firm has a market capitalization of £213.34 million, a P/E ratio of -346.15 and a beta of 1.12. The stock has a 50 day moving average price of GBX 50.85 and a 200 day moving average price of GBX 40.03.

About Avacta Group

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics. The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US. Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.